VEGFA and hereditary clear cell renal cell carcinoma: The Memorial Sloan Kettering Cancer Center (MSKCC) and the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) risk factors have been established and validated for classification of baseline prognosis in patients with mRCC treated with cytokines or VEGF-targeted agents [4–7].